• 2 months 3 weeks ago Help us improve our website: http://t.co/vY9vRzmYRH! Please take our visitor survey: http://t.co/8gY0wRZtGx. Thank you...
  • 2 months 3 weeks ago 1st European Research Forum on Healthy Ageing: 03 Sept in Bxl. Policy makers, scientists, industrials: save the date! http://t.co/6TXrBI5rdt
  • 3 months 4 days ago Gender inequalities in health: a matter of policies according to @sophieproject http://t.co/TzwZzXko3g
  • 4 months 1 day ago 1/3 of cancer patients killed by 'fat-burning' process termed cachexia, @CNIO_Cancer researchers say http://t.co/GjfipsdG2R
  • 4 months 4 weeks ago New EU research project @pneumonp aims to tackle antibiotic resistance via inhalable nano therapeutics #nanomedicine http://t.co/VQN9WHojG2
  • 5 months 2 weeks ago Urban renewal improves the health of neighbours in Barcelona according to EU-funded project @sophieproject http://t.co/F0mKCdPBZ5
  • 5 months 2 weeks ago Check this article on #CommHERE: how to spread the word about research and reach out beyond the scientific community http://t.co/VDcKVDEfcc
  • 6 months 2 weeks ago Scientists @CNIO_Cancer among the 40 most important global researchers http://t.co/Rc0hIsq6dN
  • 6 months 3 weeks ago 2nd workshop @CIBER_ISCIII to strengthen the EU‐LAC Health Research Cooperation http://t.co/93qLQObcQj
  • 8 months 2 weeks ago The European Symposium in Drug Synthesis @unisiena will take place on May 18-23. You can register until April 15!! http://t.co/V8kxQIev9S

THINPAD

Prof. Maurizio Botta

Scientific Coordinator of THINPAD, based at the University of Siena, Italy

Research field

Virology

If you like this
If you want to know more
Research Profile

Who?

Professor Botta observes the world through the eyes of a chemist. "I believe that everything is made of molecules", he says, "and my belief is that organic molecules are the key to developing a therapy against infectious diseases such as AIDS". His team is searching for molecules to fight HIV and anti-HIV drug resistance.

Why?

AIDS is one of the most serious pandemic diseases of the modern era. Therapies based on the interruption of the HIV replication cycle exist, but these therapies fail increasingly often due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies.

What?

The objective of THINPAD is to discover innovative anti-HIV agents. Professor Botta: “We develop drugs that target a protein in the shell of HIV. This protein is essential for HIV replication, so it is the Achilles' heel of the virus. We expect that HIV cannot become resistant to drugs that target this essential protein.”

How?

The THINPAD consortium brings together five teams at the forefront of HIV research. The teams are made up of two small to medium-sized enterprises in the fields of molecular biology and pharmaceutics and three academic research groups, including hospitals. The teams are located in three different EU member states.

Attacking the shell of HIV to fight drug resistance

In the Picture
In the Picture
THINPAD project website University of Siena European Centre for Disease Prevention and Control : HIV infection and AIDS World Health Organization: Q&A about HIV/AIDS IHIVARNA (another European effort to fight AIDS) In Focus article 'Off the beaten tracks' PDF versionPDF version
Image credits

Background image: C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus, CDC

Portrait of the project coordinator: THINPAD

Timeline (in chronological order): 1983: C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus, CDC; 1996: Elizabeth Glaser Pediatric AIDS Foundation; 2012: worldaidsday.org